Trial Profile
Contrast-Enhanced Ultrasound for the Evaluation of Renal Cell Carcinoma Cryoablation
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase 0
Latest Information Update: 21 Nov 2017
Price :
$35
*
At a glance
- Drugs Perflutren (Primary)
- Indications Renal cell carcinoma
- Focus Diagnostic use
- 13 Nov 2017 Planned End Date changed from 1 Nov 2020 to 4 Dec 2014.
- 13 Nov 2017 Planned primary completion date changed from 1 Nov 2020 to 4 Dec 2014.
- 17 Aug 2016 Status changed from recruiting to withdrawn prior to enrolment as the trial was terminated by IRB